Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position
Tip Ranks·
- JonesTrading analyst Debanjana Chatterjee maintained a buy rating on Trevi Therapeutics with a target price of 28.00 dollars.
- The rating is driven by the company's strong financial position and clear late stage execution in advancing its idiopathic pulmonary fibrosis chronic cough and chronic cough in renal cell carcinoma pipelines.
- Management's risk reduction strategies and robust cash balance support efficient clinical timelines, with key data expected between 2026 and 2028.